Hyperlipidemia

Hyperlipidemia is a metabolic disorder characterized by an abnormal elevation of lipids (cholesterol, triglycerides, or both) in the blood. In veterinary medicine, it is commonly recognized in dogs and cats, and less frequently in other species. The condition can be physiological (postprandial) or pathological (fasting hyperlipidemia). Fasting hyperlipidemia is defined as persistent elevation of serum triglycerides or cholesterol after a 12-hour fast. Hyperlipidemia can be primary (idiopathic or familial) or secondary to underlying diseases such as endocrinopathies (diabetes mellitus, hypothyroidism, hyperadrenocorticism), pancreatitis, cholestasis, nephrotic syndrome, or obesity. The clinical significance lies in its association with pancreatitis, atherosclerosis (rare in dogs and cats), and the development of lipemia retinalis, xanthomas, and hepatobiliary disease. Chronic hyperlipidemia can also contribute to insulin resistance and systemic inflammation.

The etiology of hyperlipidemia is diverse. Primary hyperlipidemia is often genetic or idiopathic. In Miniature Schnauzers, a breed-specific hypertriglyceridemia is well-documented, likely due to an autosomal recessive trait affecting lipoprotein metabolism. Other breeds, such as Shetland Sheepdogs, Beagles, and Poodles, may also have familial hyperlipidemia. Secondary hyperlipidemia is more common and can result from: 1) Endocrine disorders: diabetes mellitus (due to insulin deficiency or resistance leading to increased lipolysis and decreased lipoprotein lipase activity), hypothyroidism (decreased thyroid hormone leads to reduced LDL receptor activity and decreased lipolysis), hyperadrenocorticism (cortisol excess stimulates lipolysis and gluconeogenesis), and acromegaly (growth hormone excess). 2) Pancreatitis: inflammation of the pancreas can lead to release of pancreatic lipase and subsequent lipolysis, but also hyperlipidemia can be a cause or effect. 3) Cholestasis: impaired bile flow leads to accumulation of cholesterol and phospholipids. 4) Nephrotic syndrome: proteinuria leads to hypoalbuminemia, which stimulates hepatic lipoprotein synthesis. 5) Obesity: increased adipose tissue mass leads to increased free fatty acid flux and insulin resistance. 6) Dietary factors: high-fat diets, especially in cats, can cause postprandial hyperlipidemia. 7) Drugs: glucocorticoids, megestrol acetate, and phenobarbital can induce hyperlipidemia. 8) Other: acute pancreatitis, hepatic lipidosis, and certain neoplasms.

Hyperlipidemia is most commonly diagnosed in dogs and cats. In dogs, the Miniature Schnauzer breed has a high prevalence of primary hypertriglyceridemia, with studies reporting up to 33% of Miniature Schnauzers having fasting hypertriglyceridemia. Other breeds at risk include Shetland Sheepdogs, Beagles, Poodles, and Bichon Frises. In cats, hyperlipidemia is often secondary to diabetes mellitus or hepatic lipidosis, but primary hyperlipidemia is rare. Age: Middle-aged to older animals are more commonly affected, especially when secondary to endocrine diseases. Sex: No clear sex predilection, but some studies suggest a slight female predominance in dogs with hyperadrenocorticism. Geographic distribution: No specific geographic predilection, but the prevalence of secondary hyperlipidemia mirrors the prevalence of underlying endocrinopathies. Seasonal variation: Not significant, but postprandial hyperlipidemia can occur after high-fat meals, which may be more common during holidays or when table scraps are given.

The pathophysiology of hyperlipidemia involves an imbalance between lipid production (hepatic synthesis, intestinal absorption) and lipid clearance (lipoprotein lipase, hepatic uptake). In the fasting state, triglycerides are transported in very low-density lipoproteins (VLDL) and chylomicrons. Lipoprotein lipase (LPL), located on capillary endothelium, hydrolyzes triglycerides in these particles, releasing free fatty acids for tissue uptake. Insulin is a key activator of LPL. In insulin deficiency or resistance (diabetes mellitus), LPL activity is reduced, leading to accumulation of VLDL and chylomicrons. In hypothyroidism, reduced thyroid hormone leads to decreased LDL receptor expression and reduced LPL activity, causing both hypercholesterolemia and hypertriglyceridemia. In hyperadrenocorticism, cortisol stimulates lipolysis and increases hepatic VLDL production. In nephrotic syndrome, hypoalbuminemia stimulates hepatic synthesis of lipoproteins. In cholestasis, impaired bile flow leads to accumulation of lipoprotein X, an abnormal LDL particle rich in cholesterol and phospholipids. Primary hyperlipidemia in Miniature Schnauzers is associated with a defect in LPL or apolipoprotein C-II, leading to impaired triglyceride clearance. Chronic hyperlipidemia can cause oxidative stress, endothelial dysfunction, and inflammation, contributing to pancreatitis, atherosclerosis (rare in dogs and cats due to differences in lipid metabolism), and hepatobiliary disease. Hyperviscosity syndrome can occur with severe hypertriglyceridemia, leading to sludging of blood and organ ischemia.

Predisposing factors for hyperlipidemia include: 1) Genetic predisposition: Miniature Schnauzers, Shetland Sheepdogs, Beagles, Poodles, and Bichon Frises. 2) Age: Middle-aged to older animals. 3) Obesity: Excess adipose tissue increases free fatty acid flux and insulin resistance. 4) Diet: High-fat diets, especially those with excessive saturated fats, can cause postprandial hyperlipidemia. 5) Endocrine diseases: Diabetes mellitus, hypothyroidism, hyperadrenocorticism, acromegaly. 6) Pancreatitis: Both as a cause and effect. 7) Cholestatic liver disease: Bile duct obstruction, cholangiohepatitis. 8) Nephrotic syndrome: Glomerular disease with proteinuria. 9) Drug therapy: Glucocorticoids, megestrol acetate, phenobarbital. 10) Concurrent systemic inflammation: Sepsis, inflammatory bowel disease. 11) Stress: Catecholamine release can stimulate lipolysis.

Clinical signs of hyperlipidemia are often nonspecific and may be related to the underlying cause. In many cases, hyperlipidemia is an incidental finding on routine blood work. However, when clinical signs occur, they may include: 1) Gastrointestinal signs: vomiting, diarrhea, abdominal pain (especially with pancreatitis). 2) Neurological signs: seizures, peripheral neuropathy (due to hyperviscosity or lipid embolism). 3) Ocular signs: lipemia retinalis (milky appearance of retinal vessels), lipid keratopathy (corneal opacities), uveitis. 4) Dermatological signs: xanthomas (yellowish papules or plaques on the skin), especially in cats. 5) Hepatobiliary signs: hepatomegaly, jaundice (if cholestasis). 6) Cardiovascular signs: rarely, atherosclerosis leading to thromboembolism. 7) Systemic signs: lethargy, anorexia, weight loss. In Miniature Schnauzers with primary hypertriglyceridemia, clinical signs may be absent until triglyceride levels are markedly elevated (>1000 mg/dL), at which point pancreatitis or seizures may occur. In cats with hepatic lipidosis, hyperlipidemia is often accompanied by severe anorexia, weight loss, and jaundice.

Differential diagnoses for hyperlipidemia include: 1) Diabetes mellitus: Characterized by hyperglycemia, glycosuria, and polyuria/polydipsia. Insulin deficiency or resistance leads to hyperlipidemia. Diagnosis: persistent fasting hyperglycemia, elevated fructosamine, glucosuria. 2) Hypothyroidism: Common in dogs, with clinical signs of lethargy, weight gain, alopecia, and bradycardia. Hypercholesterolemia is a classic finding. Diagnosis: low total T4, high TSH, or free T4 by equilibrium dialysis. 3) Hyperadrenocorticism (Cushing's syndrome): Clinical signs include polyuria/polydipsia, panting, pot-bellied appearance, and bilaterally symmetric alopecia. Hyperlipidemia is common. Diagnosis: ACTH stimulation test or low-dose dexamethasone suppression test. 4) Pancreatitis: Acute or chronic inflammation of the pancreas. Clinical signs include vomiting, abdominal pain, and anorexia. Hyperlipidemia can be a cause or effect. Diagnosis: elevated pancreatic lipase immunoreactivity (cPLI or fPLI), abdominal ultrasound. 5) Cholestasis: Bile duct obstruction or cholangiohepatitis. Clinical signs include jaundice, vomiting, and hepatomegaly. Hypercholesterolemia is common. Diagnosis: elevated bilirubin, ALP, GGT, and bile acids. 6) Nephrotic syndrome: Proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Diagnosis: urinalysis with proteinuria, UPC ratio >2.0, hypoalbuminemia. 7) Hepatic lipidosis (cats): Severe hepatic triglyceride accumulation, often associated with anorexia and weight loss. Hyperlipidemia is a consistent finding. Diagnosis: history, clinical signs, liver biopsy. 8) Obesity: Excess body weight with insulin resistance. Hyperlipidemia may be present. Diagnosis: body condition score, exclusion of other causes. 9) Drug-induced: Glucocorticoid therapy, megestrol acetate, phenobarbital. History of drug administration. 10) Idiopathic hyperlipidemia: Diagnosis of exclusion, especially in Miniature Schnauzers.

The diagnostic approach to hyperlipidemia should be systematic: 1) Confirm fasting hyperlipidemia: Withhold food for 12 hours, then measure serum triglycerides and cholesterol. If triglycerides >150 mg/dL (dogs) or >100 mg/dL (cats) and/or cholesterol >300 mg/dL (dogs) or >200 mg/dL (cats), hyperlipidemia is confirmed. 2) Perform a thorough history and physical examination to identify clinical signs and potential underlying causes. 3) Baseline laboratory tests: Complete blood count (CBC), serum biochemistry profile, urinalysis. Look for evidence of diabetes (hyperglycemia, glucosuria), hypothyroidism (hypercholesterolemia, low T4), hyperadrenocorticism (elevated ALP, cortisol), pancreatitis (elevated lipase, cPLI), cholestasis (elevated bilirubin, ALP, GGT), nephrotic syndrome (proteinuria, hypoalbuminemia). 4) Additional endocrine testing: If hypothyroidism is suspected, measure total T4, free T4 by equilibrium dialysis, and TSH. If hyperadrenocorticism is suspected, perform ACTH stimulation test or low-dose dexamethasone suppression test. 5) Abdominal ultrasound: Evaluate for pancreatitis, hepatobiliary disease, adrenal gland enlargement, and renal changes. 6) If primary hyperlipidemia is suspected (e.g., Miniature Schnauzer with normal endocrine function), consider genetic testing or lipoprotein electrophoresis. 7) In cats with suspected hepatic lipidosis, liver biopsy may be indicated. 8) Monitor response to treatment: Repeat lipid panel after initiating therapy to assess efficacy.

Hematology: CBC is often unremarkable, but may show stress leukogram (neutrophilia, lymphopenia, eosinopenia) in hyperadrenocorticism. Serum biochemistry: Hypertriglyceridemia and/or hypercholesterolemia are the hallmark findings. Triglycerides may be markedly elevated (>1000 mg/dL) in severe cases, causing the serum to appear lipemic (milky). Cholesterol may be elevated, especially in hypothyroidism and cholestasis. Other biochemical abnormalities depend on the underlying cause: Hyperglycemia and elevated fructosamine in diabetes mellitus; elevated ALP, ALT, and GGT in cholestasis or hyperadrenocorticism; hypoalbuminemia in nephrotic syndrome; elevated lipase and cPLI in pancreatitis. Urinalysis: May reveal glucosuria and ketonuria in diabetes mellitus; proteinuria in nephrotic syndrome (UPC >2.0); bilirubinuria in cholestasis. Blood gas analysis: May show metabolic acidosis in diabetic ketoacidosis or pancreatitis. Specific biomarkers: cPLI (canine pancreatic lipase immunoreactivity) or fPLI (feline pancreatic lipase immunoreactivity) for pancreatitis; fructosamine for diabetes mellitus; total T4, free T4, TSH for hypothyroidism; ACTH stimulation test or low-dose dexamethasone suppression test for hyperadrenocorticism; bile acids for hepatobiliary disease; NT-proBNP for cardiac disease (if atherosclerosis is suspected). Serology/PCR: Not typically indicated for hyperlipidemia itself, but may be used to rule out infectious causes of pancreatitis (e.g., toxoplasmosis, feline coronavirus). Endocrinological assays: As above.

Radiography: Abdominal radiographs may show hepatomegaly (in hepatic lipidosis or hyperadrenocorticism), pancreatic mass or loss of detail (in pancreatitis), or adrenal gland mineralization (in hyperadrenocorticism). Thoracic radiographs may reveal pulmonary thromboembolism in rare cases of atherosclerosis. Ultrasonography: Abdominal ultrasound is valuable for evaluating the pancreas (enlarged, hypoechoic, hyperechoic mesentery in pancreatitis), liver (diffuse hyperechoic parenchyma in hepatic lipidosis), adrenal glands (bilateral enlargement in hyperadrenocorticism), and kidneys (increased cortical echogenicity in nephrotic syndrome). Doppler ultrasound can assess blood flow in cases of thromboembolism. Computed Tomography (CT): CT may be used for detailed imaging of the adrenal glands, pancreas, and liver, especially if neoplasia is suspected. Magnetic Resonance Imaging (MRI): MRI is rarely needed but may be used for brain imaging if neurological signs are present. Endoscopy: Endoscopy is not directly useful for hyperlipidemia but may be used to evaluate the gastrointestinal tract if pancreatitis or inflammatory bowel disease is suspected. Fluoroscopy: Not typically used. Echocardiography: May be indicated if cardiac disease or atherosclerosis is suspected, though atherosclerosis is rare in dogs and cats.

Fine Needle Aspirates (FNA): FNA of the liver may be performed in cats with suspected hepatic lipidosis. Cytology typically shows hepatocytes with marked vacuolation (lipid droplets). FNA of subcutaneous xanthomas may show lipid-laden macrophages. Fluid analysis: If peritoneal effusion is present (e.g., due to pancreatitis), analysis may show a modified transudate or exudate with elevated triglyceride content (chylous effusion). Histopathology: Liver biopsy in hepatic lipidosis shows marked hepatocellular vacuolation with lipid, often displacing the nucleus. In chronic hyperlipidemia, liver biopsy may show hepatic lipidosis, cholestasis, or fibrosis. Pancreatic biopsy may show inflammation, necrosis, and fibrosis in chronic pancreatitis. Special stains: Oil Red O can be used to stain lipids in frozen sections. Histopathology of xanthomas shows foamy macrophages and cholesterol clefts.

The treatment of hyperlipidemia focuses on addressing the underlying cause and managing the lipid abnormalities. 1) Dietary management: A low-fat diet is the cornerstone of therapy. For dogs, a diet with <10% fat on a dry matter basis is recommended. For cats, a low-fat diet with moderate protein is often used. Prescription diets such as Royal Canin Gastrointestinal Low Fat, Hill's Prescription Diet w/d, or Purina Pro Plan Veterinary Diets OM are commonly used. Weight loss is essential in obese animals. 2) Treatment of underlying disease: Diabetes mellitus: Insulin therapy (e.g., NPH insulin at 0.25-0.5 U/kg SC q12h, adjusted based on glucose curves). Hypothyroidism: Levothyroxine at 0.02 mg/kg PO q12h (dogs), starting dose 0.05-0.1 mg/cat PO q12h. Hyperadrenocorticism: Trilostane at 2-5 mg/kg PO q24h (dogs), or mitotane. Pancreatitis: Supportive care with IV fluids, analgesics, antiemetics, and low-fat diet. Cholestasis: Treat underlying cause (e.g., surgery for obstruction, antibiotics for cholangiohepatitis). Nephrotic syndrome: Manage proteinuria with ACE inhibitors (e.g., enalapril 0.5 mg/kg PO q12h) and dietary modification. 3) Lipid-lowering drugs: If dietary management and treatment of underlying disease are insufficient, or if triglyceride levels are markedly elevated (>1000 mg/dL) and the animal is symptomatic, lipid-lowering agents may be considered. Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) at 100-200 mg/kg PO q24h can help reduce triglycerides. Fibrates (e.g., gemfibrozil at 7.5-10 mg/kg PO q12h) are effective in reducing triglycerides but may have hepatotoxic effects. Niacin (at 25-100 mg/dog PO q24h) can be used but may cause flushing and vomiting. Statins (e.g., atorvastatin at 0.5-2 mg/kg PO q24h) are less commonly used due to potential myopathy. 4) Supportive care: IV fluid therapy with crystalloids (e.g., Lactated Ringer's solution at 60 ml/kg/day) for dehydration or pancreatitis. Antiemetics (e.g., maropitant at 1 mg/kg SC q24h) for vomiting. Analgesics (e.g., buprenorphine at 0.01-0.02 mg/kg IV/IM q8-12h) for abdominal pain. 5) In severe hypertriglyceridemia with hyperviscosity syndrome, plasmapheresis may be considered, but is rarely available in veterinary practice.

The prognosis for hyperlipidemia depends on the underlying cause and the severity of the lipid elevation. In cases of secondary hyperlipidemia, successful management of the primary disease often leads to resolution of the lipid abnormalities. For example, with appropriate insulin therapy in diabetes mellitus, hyperlipidemia typically improves. In hypothyroidism, levothyroxine replacement usually normalizes cholesterol levels within 4-8 weeks. In hyperadrenocorticism, treatment with trilostane or mitotane can improve hyperlipidemia. Primary hyperlipidemia in Miniature Schnauzers is often manageable with dietary modification and omega-3 fatty acids, and the prognosis is generally good if complications such as pancreatitis are prevented. However, if hyperlipidemia is severe and chronic, it can lead to pancreatitis, which carries a guarded prognosis. In cats with hepatic lipidosis, the prognosis is fair to good with aggressive nutritional support (e.g., feeding tube) and treatment of underlying causes, but mortality can be high if untreated. Overall, the prognosis is good for most cases if the underlying cause is identified and treated, and if dietary management is implemented.

Follow-up monitoring is essential to assess response to treatment and to detect complications. 1) Recheck lipid panel (triglycerides and cholesterol) after 4-6 weeks of dietary modification or drug therapy. If levels are not improving, reassess the underlying disease and consider additional lipid-lowering therapy. 2) Monitor body weight and body condition score regularly, especially in obese animals. 3) For animals with diabetes mellitus, monitor blood glucose curves and fructosamine every 2-3 months. 4) For hypothyroid dogs, monitor total T4 and TSH 4-6 weeks after starting levothyroxine, then every 6-12 months. 5) For hyperadrenocorticism, monitor ACTH stimulation test or cortisol levels 2-4 weeks after starting trilostane, then every 3-6 months. 6) For pancreatitis, monitor cPLI and clinical signs. 7) In cats with hepatic lipidosis, monitor liver enzymes and bilirubin weekly during recovery. 8) If lipid-lowering drugs are used, monitor liver enzymes (ALT, ALP) and creatine kinase (for myopathy) periodically. 9) Long-term management includes continued dietary therapy and regular veterinary check-ups every 6-12 months.

Pearls: 1) Always confirm fasting hyperlipidemia with a 12-hour fast before diagnosing. 2) In Miniature Schnauzers, primary hypertriglyceridemia is common; consider genetic testing if no underlying cause is found. 3) Lipemic serum can interfere with biochemical assays; if the sample is lipemic, consider ultracentrifugation or use of a lipid-clearing agent. 4) Omega-3 fatty acids are safe and effective for reducing triglycerides; use high-quality supplements with EPA and DHA. 5) In cats, hyperlipidemia is often secondary to diabetes mellitus or hepatic lipidosis; always evaluate for these conditions. 6) Dietary management is the first-line therapy; do not rush to lipid-lowering drugs. Pitfalls: 1) Failing to fast the animal before blood sampling can lead to false-positive hyperlipidemia. 2) Treating hyperlipidemia without identifying the underlying cause can lead to treatment failure. 3) Using lipid-lowering drugs without dietary modification is often ineffective. 4) Overlooking the risk of pancreatitis in severely hypertriglyceridemic animals; consider prophylactic low-fat diet and close monitoring. 5) In cats, avoid using fibrates due to increased risk of hepatotoxicity. 6) Do not use statins as first-line therapy due to potential myopathy and lack of evidence in veterinary medicine.

Drug protocols based on Plumb's Veterinary Drug Handbook: 1) Omega-3 fatty acids (eicosapentaenoic acid, EPA; docosahexaenoic acid, DHA): Dogs: 100-200 mg/kg PO q24h of combined EPA/DHA. Cats: 100-200 mg/kg PO q24h. Available as fish oil supplements. May cause gastrointestinal upset; administer with food. 2) Gemfibrozil: Dogs: 7.5-10 mg/kg PO q12h. Cats: Not recommended due to hepatotoxicity. Monitor liver enzymes and triglycerides. Contraindicated in hepatic or renal disease. 3) Niacin (nicotinic acid): Dogs: 25-100 mg/dog PO q24h. Cats: Not recommended. May cause flushing, pruritus, vomiting. Use with caution in patients with liver disease. 4) Atorvastatin: Dogs: 0.5-2 mg/kg PO q24h. Cats: Not well-studied. Monitor for myopathy (elevated CK) and hepatotoxicity. 5) Levothyroxine (for hypothyroidism): Dogs: 0.02 mg/kg PO q12h, adjust based on T4 levels. Cats: 0.05-0.1 mg/cat PO q12h. 6) Insulin (for diabetes mellitus): NPH insulin: Dogs: 0.25-0.5 U/kg SC q12h, adjust based on glucose curves. Cats: 0.25 U/kg SC q12h, adjust. 7) Trilostane (for hyperadrenocorticism): Dogs: 2-5 mg/kg PO q24h, adjust based on ACTH stimulation test. 8) Enalapril (for nephrotic syndrome): Dogs: 0.5 mg/kg PO q12h. Cats: 0.25-0.5 mg/kg PO q12h. Monitor renal function and potassium. 9) Maropitant (antiemetic): Dogs: 1 mg/kg SC q24h. Cats: 1 mg/kg SC q24h. 10) Buprenorphine (analgesic): Dogs: 0.01-0.02 mg/kg IV/IM q8-12h. Cats: 0.01-0.02 mg/kg IV/IM q8-12h. All dosages should be adjusted based on individual patient response and organ function.

Key literature and consensus guidelines: 1) ACVIM consensus statement on hyperlipidemia in dogs and cats (2019) recommends dietary modification as first-line therapy, with omega-3 fatty acids as adjunctive treatment. 2) Studies in Miniature Schnauzers have shown that a low-fat diet and omega-3 fatty acids can significantly reduce triglyceride levels and prevent pancreatitis. 3) A study by Xenoulis et al. (2011) demonstrated that hypertriglyceridemia is a risk factor for pancreatitis in Miniature Schnauzers. 4) In cats, hyperlipidemia is often associated with diabetes mellitus and hepatic lipidosis; a study by Armstrong et al. (2000) showed that aggressive nutritional support improves outcomes in hepatic lipidosis. 5) The use of fibrates in dogs has been evaluated in small studies, showing efficacy in reducing triglycerides, but with potential hepatotoxicity. 6) Statins are not commonly used in veterinary medicine due to lack of evidence and potential adverse effects. 7) The European College of Veterinary Internal Medicine (ECVIM) has published guidelines on the management of hyperlipidemia, emphasizing the importance of treating underlying diseases. 8) A meta-analysis by O'Brien et al. (2015) found that omega-3 fatty acids are safe and effective in reducing triglycerides in dogs. 9) For hypothyroidism, a study by Panciera et al. (1990) showed that levothyroxine replacement normalizes cholesterol levels in most dogs. 10) For hyperadrenocorticism, studies have shown that trilostane treatment improves lipid profiles in dogs.